Partial Response to First-Line Crizotinib in an Elderly Male Patient with ROS1 Translocation-Positive Lung Cancer

We report on a 90-year-old male patient with a ROS1-translocated adenocarcinoma of the lung who was treated with crizotinib as first-line therapy. After 11 months of treatment, we noticed complete metabolic response as measured by (18)F-FDG-PET/CT scan and a partial response according to RECIST crit...

Descripción completa

Detalles Bibliográficos
Autores principales: Overbeck, Tobias R., Schmitz, Katja, Engelke, Christoph, Sahlmann, Carsten-Oliver, Hugo, Sara, Kellner, Laura, Trümper, Lorenz, Schildhaus, Hans-Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2016
Materias:
Published online: March, 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821145/
https://www.ncbi.nlm.nih.gov/pubmed/27065847
http://dx.doi.org/10.1159/000444745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821145/
https://www.ncbi.nlm.nih.gov/pubmed/27065847
http://dx.doi.org/10.1159/000444745

Ejemplares similares